**Neuroendocrine/Endocrine**

**Poorly Differentiated-NEC (any extrapulmonary neuroendocrine carcinoma with small cell or large cell histology)**

10402: BAY1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients with Advanced Solid Tumors, Phase I Studies with Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)

**Neuroendocrine Cancer**

*10558*: A phase II randomized control trial of triapine plus lutetium 177 dotatate versus lutetium 177 dotatate alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors

10388: A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

10450: A Phase 1b Study of M3814 (Peposertib) in Combination with Lutetium 177 Dotatate in Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

*10479*: A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate Plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors

**GI (Gastroenteropancreatic / Pancreatic tumors)**

*10487*: A Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer with Neuroendocrine Differentiation

**Prostate Cancer**

*10487*: A Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer with Neuroendocrine Differentiation

**NOTE:** * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: December 8, 2022